

Aleksey S Kolbin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3314627/publications.pdf>

Version: 2024-02-01

60
papers

225
citations

1306789

7
h-index

1125271

13
g-index

60
all docs

60
docs citations

60
times ranked

317
citing authors

#	ARTICLE	IF	CITATIONS
1	Mucormycosis in haematological patients: case report and results of prospective study in Saint Petersburg, Russia. <i>Mycoses</i> , 2014, 57, 91-96.	1.8	27
2	A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 8, 148-156.	0.9	24
3	Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of pharmacoepidemiological study (FOR SIGHT-DM2). <i>Diabetes Mellitus</i> , 2016, 19, 443-456.	0.5	23
4	Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FOR SIGHT-Ð2DM). <i>Diabetes Mellitus</i> , 2017, 20, 403-419.	0.5	18
5	MUCORMYCOSIS IN ONCOHEMATOLOGY PATIENTS (results of the prospective study). <i>Oncogematologiya</i> , 2017, 12, 14-22.	0.1	9
6	What should be considered if you decide to build your own mathematical model for predicting the development of bacterial resistance? Recommendations based on a systematic review of the literature. <i>Frontiers in Microbiology</i> , 2015, 6, 352.	1.5	8
7	«DIARISK» – the first national prediabetes and diabetes mellitus type 2 risk calculator. <i>Diabetes Mellitus</i> , 2021, 23, 404-411.	0.5	8
8	Resolution based on the results of the conference: "RWD/ RWE – Research Tools of Real-World Clinical Practice Today and Tomorrow"., 2021, 1, 21-24.		8
9	The social-economic burden of spinal muscular atrophy in Russia. <i>Farmakoekonomika</i> , 2021, 13, 337-354.	0.4	7
10	Socio-economic burden of COVID-19 in the Russian Federation. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 35-44.	0.2	7
11	Brief report of real-world evidence development (RWD/RWE) in 2021: United States, Russia, and the Eurasian Economic Union (EAEU)., 2022, 2, 1-9.		7
12	The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies. <i>Farmakoekonomika</i> , 2022, 15, 87-105.	0.4	7
13	Socioeconomic and global burden of COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, 20, 24-34.	0.2	6
14	Review of real-world data study. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, 20, 56-63.	0.2	6
15	The data retrieval optimization from the perspective of evidence-based medicine. , 0, , .		4
16	Improving data retrieval quality: Evidence based medicine perspective. <i>International Journal of Risk and Safety in Medicine</i> , 2015, 27, S106-S107.	0.3	4
17	COMPARATIVE REVIEW OF METHODOLOGIES FOR ESTIMATING THE COST OF ADVERSE DRUG REACTIONS IN THE RUSSIAN FEDERATION AND BRAZIL. <i>Farmatsiya I Farmakologiya</i> , 2021, 8, 336-344.	0.2	4
18	An economic value of the glycosylated hemoglobin test in diabetes mellitus type 2 diagnosis. <i>Diabetes Mellitus</i> , 2019, 22, 504-514.	0.5	4

#	ARTICLE	IF	CITATIONS
19	Pragmatic clinical trials. Kachestvennaya Klinicheskaya Praktika, 2020, , 52-60.	0.2	4
20	Health economic evaluation of risdiplam in patients with spinal muscular atrophy. Farmakoekonomika, 2021, 14, 299-310.	0.4	3
21	A Pharmacoeconomic Analysis of Treating Severe Uncontrolled Child Asthma with Omalizumab – Actual Russian Clinical Practice Data. PediatriĀeskaĀ FarmakologiĀ, 2016, 13, 345-353.	0.1	3
22	Modeling microbial drug-resistance: from mathematics to pharmacoeconomics. Farmakoekonomika, 2018, 11, 27-36.	0.4	3
23	Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg. Kachestvennaya Klinicheskaya Praktika, 2022, , 80-84.	0.2	3
24	Real-world evidence market: key players and key segments. , 2022, 2, 40-43.		3
25	PSY32 COST-EFFECT ANALYSIS OF THE USE OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES COMPARED TO FLUCONAZOLE AND ITRACONAZOLE IN PATIENTS WITH PRONOUNCED NEUTROPENIA. Value in Health, 2010, 13, A211.	0.1	2
26	Optimization Approach for Estimating the Required Amount of Pharmaceuticals in the Russian Federation. Value in Health Regional Issues, 2018, 16, 39-45.	0.5	2
27	Applying real-world data to support regulatory decision – making in the United States. Kachestvennaya Klinicheskaya Praktika, 2021, 20, 64-69.	0.2	2
28	An early assessment of the efficacy of medicines in the treatment of patients with COVID-19. Russian Journal of Infection and Immunity, 2020, 10, 277-286.	0.2	2
29	Nonsteroidal anti-inflammatory drugs – adverse drug reactions: 10 years of national database data. Kachestvennaya Klinicheskaya Praktika, 2022, , 16-26.	0.2	2
30	P974 Antifungal chemoprophylaxis in the very low birth weight neonates: a prospective randomised controlled study. International Journal of Antimicrobial Agents, 2007, 29, S258.	1.1	1
31	PGI25 PHARMACOECONOMIC ANALYSIS OF THE EFFECTS OF SECONDARY BACTERIAL RESISTANCE IN THE MULTI-DEPARTMENTAL HOSPITAL ON TREATMENT EFFICACY IN COMPLICATED ABDOMINAL INFECTIONS. Value in Health, 2010, 13, A73.	0.1	1
32	Pharmacoeconomic Analysis of the use of Everolimus Compared to Axitinib in Second Line Therapy of Patients with Metastatic Renal Cell Carcinoma. Value in Health, 2015, 18, A442.	0.1	1
33	Development Of Predictive Models For The Analysis Of The List Of Vital Essential And Necessary Drugs Compilation. Value in Health, 2016, 19, A448.	0.1	1
34	Cystic fibrosis as a social-economic burden. Kachestvennaya Klinicheskaya Praktika, 2021, , 38-49.	0.2	1
35	Legal aspects of conducting real-world studies. Kachestvennaya Klinicheskaya Praktika, 2021, , 64-69.	0.2	1
36	Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapy. Problemy Endokrinologii, 2017, 63, 307-319.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Clinical Trials in Pediatrics and Neonatology: Reasons for Ups and Downs. <i>PediatricĀeskaĀĀ FarmakologiĀĀ</i> , 2016, 13, 232-238.	0.1	1
38	Invasive aspergillosis in children and adolescents with solid tumors: clinical cases and registry analysis. <i>Oncogematologiya</i> , 2019, 14, 40-48.	0.1	1
39	Comparative modeling of socio-economic burden among smokers, nonsmokers and former smokers. <i>Farmakoekonomika</i> , 2019, 12, 65-71.	0.4	1
40	Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 23-34.	0.2	1
41	Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 4-21.	0.2	1
42	Health Technologies Assessment for Orphan Diseases. Example of Social and Economic Burden of Spinal Muscular Atrophy. <i>PediatricĀeskaĀĀ FarmakologiĀĀ</i> , 2021, 18, 408-415.	0.1	1
43	Why do we need "Real-World Data & Evidence", the new scientific electronic journal?. , 2021, 1, 2-4.		1
44	Chinese experience on using RWE to support drug research, development and evaluation. , 2022, 2, 17-27.		1
45	PDB26 THE PHARMACOECONOMIC STUDY OF INSULIN GLRAGINE USAGE IN ROUTINE CLINICAL PRACTICE IN RUSSIAN FEDERATION. <i>Value in Health</i> , 2009, 12, A406.	0.1	0
46	PIN33 A CLINICAL-ECONOMIC STUDY OF CASPOFUNGIN THERAPY IN THE TREATMENT OF INVASIVE CANDIDIASIS IN RESUSCITATION AND INTENSIVE CARE UNITS. <i>Value in Health</i> , 2010, 13, A192.	0.1	0
47	Cost-Effectiveness Analysis of Use of Dydrogesterone in Premenstrual Syndrome. <i>Value in Health</i> , 2014, 17, A508.	0.1	0
48	Budget Impact Analysis of the Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors ĀĀ Nilotinib in the First and Second Lines of Therapy. <i>Value in Health</i> , 2015, 18, A443.	0.1	0
49	Investigating Levels of Bacterial Resistance and Antibiotic Consumption in the St. Petersburg State Medical University. <i>Value in Health</i> , 2015, 18, A515-A516.	0.1	0
50	Parametric and Non-Parametric Approaches for Predicting Bacterial Resistance. <i>Value in Health</i> , 2016, 19, A441-A442.	0.1	0
51	Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 50-63.	0.2	0
52	Clinical-economic evaluation of a screening for Pompe disease in children in the local conditions. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021, , 27-37.	0.2	0
53	The Use of Biotechnological Drugs in Pediatrics on the Example of Monoclonal Antibodies: Clinical Pharmacology View. <i>PediatricĀeskaĀĀ FarmakologiĀĀ</i> , 2021, 18, 304-313.	0.1	0
54	Current Problems in Provision of Orphan Drugs and Ways to Solve Them. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2016, 15, 344-351.	0.1	0

#	ARTICLE	IF	CITATIONS
55	PHARMACOEPIDEMOLOGY OF ANTIMICROBIAL AGENTS IN NEONATOLOGY: RESULTS OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 2016, 15, 481-488.	0.1	0
56	CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation. Farmakoekonomika, 2018, 11, 19-26.	0.4	0
57	What is the role of antineoplastic drug safety in reimbursement decision making?. Farmakoekonomika, 2018, 11, 38-42.	0.4	0
58	A systematic review of real-world clinical practice data in COVID-19: non-interventional studies. Farmakoekonomika, 2022, 15, 145-161.	0.4	0
59	The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults. Kachestvennaya Klinicheskaya Praktika, 2022, , 4-16.	0.2	0
60	Clinical-economic analysis of the target therapy in severe atopic dermatitis in adults. Kachestvennaya Klinicheskaya Praktika, 2022, , 17-29.	0.2	0